TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00089050
Drug: gemtuzumab ozogamicin
Normalized name: Gemtuzumab Ozogamicin
DrugBank: Gemtuzumab ozogamicin (DB00056)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT04360980
Drug: Colchicine Tablets
Normalized name: Colchicine Tablets
DrugBank: Colchicine (DB01394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1.5 mg loading then 0.5 mg BID P.O
Study: NCT04402970
Drug: Dornase Alfa Inhalation Solution
Normalized name: Dornase Alfa Inhalation Solution
DrugBank: Dornase alfa (DB00003)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nebulized dornase alfa
Study: NCT01251848
Drug: Sitaxentan
Normalized name: Sitaxentan
DrugBank: Sitaxentan (DB06268)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Sitaxsentan Tablet, 100 mg, q24h (once daily) for 5 days.
Study: NCT01251848
Drug: Ritonavir
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ritonavir Capsule, 100 mg, q12h (twice daily) for 5 days (morning dose only on Day 5).
Study: NCT01251848
Drug: Sitaxsentan
Normalized name: Sitaxsentan
DrugBank: Sitaxentan (DB06268)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Sitaxsentan Tablet, 100 mg, q24h (once daily) for 5 days
Study: NCT01251848
Drug: Ritonavir
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ritonavir Capsule, 100 mg, q12h (twice daily) for 5 days
Study: NCT01641900
Drug: eszopiclone
Normalized name: Eszopiclone
DrugBank: Eszopiclone (DB00402)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3 mg of eszopiclone for two consecutive nights (Baseline Night and Experimental Night). Sleep spindle density (primary outcome) is measured for both nights. Memory consolidation (secondary outcome) is measured over Experimental Night.
Study: NCT00702884
Drug: sunitinib malate
Normalized name: Sunitinib Malate
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sunitinib 37.5 mg daily for a 4 week cycle
Study: NCT02185794
Drug: Voxilaprevir
Normalized name: Voxilaprevir
DrugBank: Voxilaprevir (DB12026)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Voxilaprevir tablets administered orally once daily
Study: NCT02185794
Drug: Placebo to match voxilaprevir
DrugBank: Voxilaprevir (DB12026)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Placebo to match voxilaprevir tablets administered orally once daily
Study: NCT02987218
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous hypnotic agent Decrease Cerebral Metabolic reduction Decrease ICP Better cognitive Function preservation
Study: NCT02987218
Drug: Desflurane
Normalized name: Desflurane
DrugBank: Desflurane (DB01189)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhalational agent. Decreases cerebral metabolism Increase /decreases ICP Cognition preservation
Study: NCT00073372
Drug: Abciximab
Normalized name: Abciximab
DrugBank: Abciximab (DB00054)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01673594
Drug: SODAS MPH
Normalized name: MPH
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adults with ADHD will receive open-label SODAS MPH
Study: NCT01673594
Drug: Naltrexone
Normalized name: Naltrexone
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects randomized to the active double-blind group will receive Naltrexone HCl
Study: NCT00794807
Drug: Alefacept
Normalized name: Alefacept
DrugBank: Alefacept (DB00092)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alefacept=LFA-3/IgG1 fusion protein, once weekly, 15mg i.m.
Study: NCT00199056
Drug: Vincristine / Vindesine
DrugBank: Vindesine (DB00309)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00199056
Drug: Daunorubicin
Normalized name: daunorubicin
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00627653
Drug: fenofibrate
Normalized name: Fenofibrate
DrugBank: Fenofibrate (DB01039)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 148mg daily for 30 days
Study: NCT03112889
Drug: Sodium Valproate
Normalized name: sodium valproate
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will receive sodium valproate modified release 20mg/kg/day (maximum dose 2.0g/day) administered orally once daily for six months.
Study: NCT03852862
Drug: Serratus plane block and paravertebral block
Normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single Administration of 20 mL of ropivacaine for Serratus plane block (Intra-muscular injection) followed by a single administration of 20 ml ropivacaine for paravertebral block (T4 inter-vertebral injection)
Study: NCT03852862
Drug: paravertebral block
Normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single Administration of 20 ml of ropivacaine for paravertebral block (T4 inter-vertebral injection)
Study: NCT04539470
Drug: Efmarodocokin Alfa
Normalized name: Efmarodocokin alfa
DrugBank: Efmarodocokin alfa (DB16398)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efmarodocokin Alfa will be administered intravenously (IV) per the dosage specified in each dose escalation cohort.
Study: NCT00807742
Drug: Nicotine Replacement Treatment (NRT)
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicoderm CQ nicotine skin patch: 21mg patch for 4 weeks, 14mg patch for 2 weeks, 7mg patch for 2 weeks. This is supplemental intervention provided to all.
Study: NCT00199056
Drug: Asparaginase
Normalized name: Asparaginase
DrugBank: Asparaginase Escherichia coli (DB00023)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00199056
Drug: G-CSF
Normalized name: G-CSF
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00199056
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00199056
Drug: 6-Mercaptopurine
Normalized name: 6-Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00199056
Drug: VP16
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00199056
Drug: Adriamycin
Normalized name: Adriamycin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00199056
Drug: Thioguanine
Normalized name: Thioguanine
DrugBank: Tioguanine (DB00352)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00199056
Drug: VM26
Normalized name: Teniposide
DrugBank: Teniposide (DB00444)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00199056
Drug: Idarubicin
Normalized name: Idarubicin
DrugBank: Idarubicin (DB01177)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00199056
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00199056
Drug: Ifosfamide
Normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02379000
Drug: Triamcinolone Acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Under sterile conditions an intravitreal injection of trimcinolone acetonide 4 mg was performed.
Study: NCT00010049
Drug: imatinib mesylate
Normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02193165
Drug: triclosan/fluoride toothpaste + cetylpyridinium chloride Mouthwash
DrugBank: Triclosan (DB08604)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brush whole mouth with Total toothpaste for 1 minute, 2 times/day for 6 weeks (study duration) using a Total 360 toothbrush. Immediately after each toothbrushing, rinse whole mouth with 20 ml of mouthwash for 30 seconds.
Study: NCT02193165
Drug: stannous fluoride toothpaste + cetylpyridinium chloride Mouthwash
Normalized name: cetylpyridinium chloride / sodium fluoride Toothpaste
DrugBank: Cetylpyridinium (DB11073)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brush whole mouth with Crest Pro-Health toothpaste for 1 minute, 2 times/day for 6 weeks (study duration) using an Oral B Pro-Health toothbrush. Immediately after each toothbrushing, rinse whole mouth with 20 ml of Crest Pro-Health Multi-Protection mouthwash for 30 seconds.
Study: NCT02193165
Drug: fluoride toothpaste + fluoride Mouthwash
Normalized name: sodium fluoride Toothpaste [Fluoridex]
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brush whole mouth with Crest Cavity Protection toothpaste for 1 minute, 2 times/day for 6 weeks (study duration) using an Oral B Indicator toothbrush. Immediately after each toothbrushing, rinse whole mouth with 20 ml of Crest Pro-Health For Me Breezy Mint mouthwash for 30 seconds.
Study: NCT03407781
Drug: 68Ga-BBN-IRDye800CW
Normalized name: 68Ga-DOTATOC
DrugBank: Dotatate gallium Ga-68 (DB13925)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PET/NIR fluorescent imaging-guided surgery
Study: NCT00658619
Drug: 400 µg Brimonidine Tartrate Implant
Normalized name: Brimonidine Tartrate
DrugBank: Brimonidine (DB00484)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 400 µg brimonidine tartrate implant in the study eye on Day 1 and Month 6.
Study: NCT00658619
Drug: 200 µg Brimonidine Tartrate Implant
Normalized name: Brimonidine Tartrate
DrugBank: Brimonidine (DB00484)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 200 µg brimonidine tartrate implant in the study eye on Day 1 and Month 6.
Study: NCT03092232
Drug: PF-06865571
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single ascending dose of PF-06865571 as extemporaneously prepared solution/suspension, once every 2 week in a cross over study: 5 mg, 50 mg, 500 mg, TBD (to be determined)/2000 mg.
Study: NCT00410774
Drug: gemcitabine hydrochloride
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03967223
Drug: Letetresgene autoleucel (lete-cel, GSK3377794)
Normalized name: Brexucabtagene autoleucel
DrugBank: Letetresgene autoleucel (DB17233)
Approvals — FDA: no, EMA: no, PMDA: no
Description: letetresgene autoleucel will be administered.
Study: NCT03967223
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine will be used as the lymphodepleting chemotherapy
Study: NCT01900626
Drug: epidural catheter
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: epidural catheter with 0.3% ropivacaine
Study: NCT03092232
Drug: PF-06865571
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single ascending dose of PF-06865571 as extemporaneously prepared solution/suspension, once every 2 week in a cross over study: 15 mg, 150 mg, 1000 mg, TBD/2000 mg.
Study: NCT03901768
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: a syringe having 4ml of 4mg/ml of dexamethasone is used for intravenous injection.
Study: NCT03901768
Drug: Triamcinolone
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1ml of 40mg triamcinolone is mixed in the syringes containing solution for intrarticualar local infiltration. The solution is injected intraarticularly.
Study: NCT03092232
Drug: PF-06865571
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single repeated (TBD mg) dose as extemporaneously prepared solution/suspension of PF-06865571.
Study: NCT02363803
Drug: lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: lidocaine is a sodium channel blocker/analgesic. It is approved for intravenous administration for cardiac arrhythmias.
Study: NCT02865005
Drug: Dapsone 5.0% Gel (SEEGPharm)
DrugBank: Dapsone (DB00250)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical Gel
Study: NCT00327093
Drug: cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: indication : second intention treatment
Study: NCT00327093
Drug: bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Indication: first intention treatment
Study: NCT03600064
Drug: Misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: the women will be received two tablets of misoprostol 400 mcg vaginally before IUD removal (Misotac®; Sigma Pharma, SAE, Egypt).
Study: NCT03817554
Drug: Pramipexole
Normalized name: Pramipexole
DrugBank: Pramipexole (DB00413)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pramipexole will be taken once daily in the evening 2 to 3 hours before bedtime. The starting dose of pramipexole is 0.125 mg/day. During the first 4 weeks, the daily dose could be increased by the treating physician in weekly intervals to 0.25, 0.50, or 0.75 mg/day, according to the Patient Global Impression scale (PGI) rating and overall tolerability of the drug. In the case of adverse events (AEs), the dose could be reduced to the previous dose step. During 5 to 12 weeks, the dose will keep constant.
Study: NCT01483742
Drug: danoprevir
Normalized name: Danoprevir
DrugBank: Danoprevir (DB11779)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg orally bid, 24 weeks
Study: NCT01483742
Drug: peginterferon alfa-2a [Pegasys]
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 180 mcg weekly, 24 weeks
Study: NCT02865005
Drug: Dapsone 5.0% Gel (Allergan)
DrugBank: Dapsone (DB00250)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical Gel
Study: NCT04060147
Drug: Cilofexor
Normalized name: Cilofexor
DrugBank: Cilofexor (DB15168)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets administered orally once daily
Study: NCT00578552
Drug: Gabapentin - 1800 mg/day
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: gabapentin - 1800 mg/day for 12 weeks.
Study: NCT00578552
Drug: Gabapentin - 2700 mg/day
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: gabapentin - 2700 mg/day for 12 weeks.
Study: NCT03575403
Drug: Alcohol
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In each arm, subjects will receive doses of alcohol, designed to raise BALs to 0.015 and 0.03 g/dl.
Study: NCT03575403
Drug: Duloxetine
Normalized name: Duloxetine
DrugBank: Duloxetine (DB00476)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will receive duloxetine capsules.
Study: NCT03575403
Drug: Methylphenidate
Normalized name: Methylphenidate
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will receive methylphenidate capsules.
Study: NCT01667679
Drug: 100 mg Sumatriptan Tablet and OPTINOSE Placebo delivered nasally
DrugBank: Sumatriptan (DB00669)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01667679
Drug: OPTINOSE SUMATRIPTAN delivered nasally and placebo tablet
Normalized name: sumatriptan Nasal Spray
DrugBank: Sumatriptan (DB00669)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02313194
Drug: Buspirone
Normalized name: Buspirone
DrugBank: Buspirone (DB00490)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Determine if the pharmacological agent in combination with the stimulator can improve motor function.
Study: NCT01483742
Drug: ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000-1200 mg/kg/day orally in two divided doses, 24 weeks
Study: NCT01483742
Drug: ritonavir
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 100 mg orally bid, 24 weeks
Study: NCT01415011
Drug: Afatinib (BIBW 2992)
Normalized name: Afatinib
DrugBank: Afatinib (DB08916)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: All patients will be given daily oral afatinib (BIBW 2992) administered every 28 days until disease progression/toxicity/clinician decision to stop. Starting dose is 40mg. 30mg and 20mg will be administered according to protocol dose modification requirements following toxicity.
Study: NCT04097613
Drug: Povidone-Iodine
Normalized name: Povidone-Iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Povidone Iodine solution 5% (0.5% available iodine) by 3MTM has been specially formulated as a nasal antiseptic. They have shown topical application to be clinically safe, tolerable and to be rapidly bacteriocidal against aerobic gram positive and gram- negative bacteria including methicillin resistant Staphylococcus aureus, methicillin resistant Staphylococcus epidermidis, vancomycin resistant Enterococcus faecium and Enterococcus faecalis (VRE) and yeast (3M study 05-011100,05-011017, 05-011322).
Study: NCT04097613
Drug: Budesonide
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide is is provided in nebules (1mg/2cc). Patients will place two nebules of budesonide into the 250mls of saline.
Study: NCT03236220
Drug: N-acetyl-L-cysteine
Normalized name: N-acetyl-L-cysteine
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acute leukemia patients with complete remission, whose bone marrow endothelial cells were less than 0.1% detected before haploidentical hematopoietic stem cell transplantation, receive N-acetyl-L-cysteine (NAC) (orally at dosages of 400mg 3 times per day). NAC treatment begins from 14 days pre-allotransplant to 2 months after-allotransplant continuously in the absence of disease progression or unacceptable toxicity.
Study: NCT00025220
Drug: Thalidomide
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT04202679
Drug: Dupilumab SAR231893
DrugBank: Dupilumab (DB12159)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pharmaceutical form:Injection solution Route of administration: Subcutaneous
Study: NCT04202679
Drug: Low to medium potent topical corticosteroids
Normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:~Route of administration: Topical
Study: NCT04910178
Drug: Empagliflozin 25 MG
Normalized name: empagliflozin 25 MG
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: tablets to be taken orally once a day
Study: NCT04910178
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablets to be taken orally twice a day
Study: NCT04910178
Drug: Pentoxifylline 400 MG
Normalized name: pentoxifylline 400 MG
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: tablets to be taken orally twice a day
Study: NCT00857389
Drug: Thiotepa
Normalized name: Thiotepa
DrugBank: Thiotepa (DB04572)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 5 mg/kg through a central venous catheter (CVC) over 2 hours on Day -8.
Study: NCT00489307
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 4 mg PO (by mouth) twice daily x 14 days
Study: NCT02777580
Drug: Tenecteplase
Normalized name: Tenecteplase
DrugBank: Tenecteplase (DB00031)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Half dose Tenecteplase
Study: NCT02777580
Drug: Clopidogrel
Normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 300 mg p.o. initial loading dose. Maintenance dose of 75 mg p.o. once daily. The maintenance dose of Clopidogrel (75 mg p.o. per day) should be continued for 1 year.
Study: NCT01629381
Drug: Rivaroxaban
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 10 mg os once daily for 1 week
Study: NCT02169115
Drug: Omalizumab
Normalized name: Omalizumab
DrugBank: Omalizumab (DB00043)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 150mg, s.c., every 4 weeks
Study: NCT02169115
Drug: Omalizumab
Normalized name: Omalizumab
DrugBank: Omalizumab (DB00043)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 300mg, s.c., every 4 weeks
Study: NCT03646617
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab (1 mg/kg) will be administered as an IV infusion over 30 minutes, followed by ipilimumab (3 mg/kg) on the same day given as an IV infusion over 90 minutes. The two drugs will be given on day 1, then every 3 weeks for a total of four doses. After these 4 doses, the patient and investigator will decide to continue with nivolumab (240 mg) every 2 weeks or Nivolumab (480mg) every 4 weeks as monotherapy for up to one year as an IV infusion over 30 minutes.
Study: NCT03646617
Drug: Ipilimumab
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab (1 mg/kg) will be administered as an IV infusion over 30 minutes, followed by ipilimumab (3 mg/kg) on the same day given as an IV infusion over 90 minutes. The two drugs will be given on day 1, then every 3 weeks for a total of four doses.
Study: NCT01534520
Drug: Lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravaginal insertion of 4mL 2% lidocaine gel
Study: NCT03325192
Drug: Rapid pleurodesis protocol
Normalized name: Abreva Rapid Pain Relief
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: * The pleural space will be evacuated completely through the newly placed IPC~* 20mL of 10% iodopovidone and 80mL of normal saline will be instilled into the pleural space~* The patient will be transferred to the recovery unit~* Two hours after instillation the pleural space will be drained~* After recovery from anesthesia and complete drainage of the pleurodesis mix, the subject will be discharged~* Subjects will be asked to drain their effusion on a daily basis for the next 7 days and then on an every other day basis.
Study: NCT03846765
Drug: Phenylephrine
Normalized name: Phenylephrine
DrugBank: Phenylephrine (DB00388)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phenylephrine will be administered continuously after intubation in order to maintain blood pressure in a range from MAPbaseline -20% to normal (preoperative) values (MAPbaseline). If MAP decreases to a value lower than MAPbaseline -20%, a higher dose of vasopressor will be administered. If MAP increases to a value above MAPbaseline, the dosing rate will be decreased.~Phenylephrine will be started at 0,2 μg/kg/min and adjusted according to the patient's hemodynamic status. The dose will be adjusted to MAP during a 30-minute study period.
Study: NCT01996852
Drug: sildenafil citrate
Normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100mg of sildenafil citrate will be given twice a week to interested patients. Participants may start Sildenafil at a lower dose when needed.~To increase external validity, participants will be given the choice of using Sildenafil in the study.